What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and furnish Amgen Inc.'s unaudited financial results for the fourth quarter and full year ended December 31, 2025, through a press release (Exhibit 99.1). The filing emphasizes the presentation of non-GAAP financial measures to offer investors additional insights into the company's performance.

What types of expenses does Amgen exclude when calculating its non-GAAP financial measures?

Amgen excludes several types of expenses to calculate its non-GAAP financial measures. These include acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs associated with restructuring and cost savings initiatives (like facility charges and severance), and certain other items considered outside the ordinary course of business, such as gains/losses on equity investments and costs related to legal proceedings.

Are the non-GAAP financial measures presented in this filing considered more important than GAAP measures?

No, Amgen states that its non-GAAP financial measures are presented as supplementary information and are not a substitute for, or superior to, measures prepared in accordance with GAAP. The company believes these non-GAAP measures enhance an investor's overall understanding of financial performance and facilitate comparisons of ongoing business operations.

Where can I find the detailed financial results and reconciliations for the non-GAAP measures?

The detailed financial results for the fourth quarter and full year 2025, including reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures, are provided in the press release furnished as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed an 8-K report on February 3, 2026, announcing its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The report primarily furnishes a press release detailing these results, which includes a significant focus on non-GAAP financial measures. These non-GAAP measures, such as non-GAAP earnings per share, operating income, and margins, are presented to provide investors with a more comprehensive understanding of the company's ongoing business performance and facilitate comparisons across periods. The company explicitly states its belief that these non-GAAP metrics, alongside Free Cash Flow (FCF) and a debt leverage ratio, offer valuable supplementary insights. Amgen utilizes these measures internally for budgeting, financial planning, and performance evaluation. Key adjustments to GAAP figures include the exclusion of acquisition-related expenses, restructuring and cost savings initiatives, and certain other items like investment gains/losses and legal proceeding costs. Investors should note that these non-GAAP measures are not a substitute for GAAP reporting but are intended to enhance analytical perspectives.

Key Highlights

1Amgen Inc. released its unaudited Q4 and full-year 2025 financial results on February 3, 2026.
2The report heavily features non-GAAP financial measures to provide supplemental performance insights.
3Key non-GAAP metrics include adjusted earnings per share, operating income, and operating margin.
4The company also highlights Free Cash Flow (FCF) and a debt leverage ratio in its reporting.
5Adjustments to GAAP include acquisition-related expenses, restructuring costs, and certain investment/legal items.
6Amgen management uses these non-GAAP measures for internal budgeting, planning, and performance evaluation.
7The furnished press release (Exhibit 99.1) contains detailed reconciliations of non-GAAP to GAAP measures.

AMGEN INC 8-K Report, Financial Results (Feb 3, 2026)

Summary

Key Highlights

Frequently Asked Questions